A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

Stopped The HVTN 303 IND was placed on clinical hold, and recruitment did not resume.

Conditions

• HIV

Interventions

• BIOLOGICAL: FP conjugate vaccine (25 mcg)
• BIOLOGICAL: FP conjugate vaccine (200 mcg)
• BIOLOGICAL: Trimer 6931 (100 mcg)
• BIOLOGICAL: Trimer 6931 (200 mcg)
• BIOLOGICAL: Trimer 4571 (200 mcg)
• BIOLOGICAL: Trimer 4571 (100 mcg)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

• [object Object]
• [object Object]